{"id":212101,"name":"RARE DISEASE COMPANY COALITION","slug":"rare-disease-company-coalition","state":"DC","country":"United States of America","description":"Companies committed to discovering, developing, & delivering rare disease treatment","totalSpending":1100000,"filings":17,"yearlySpending":[{"year":2021,"income":120000},{"year":2022,"income":180000},{"year":2023,"income":240000},{"year":2024,"income":560000}],"issues":[{"code":"HCR","display":"Health Issues"},{"code":"PHA","display":"Pharmacy"},{"code":"MMM","display":"Medicare/Medicaid"}],"firms":["THE KPM GROUP DC LLC"],"lobbyists":["PATROSKI LAWSON","BENJAMIN MASON","KATHERINE LANDES","JACOB JACKSON","YOKO ROSENBAUM","AMANDA MALAKOFF","STACEY FRISK","PAULA GUTIERREZ"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE","Health & Human Services, Dept of (HHS)","Food & Drug Administration (FDA)","Natl Institutes of Health (NIH)"],"sampleDescriptions":["Treatment of rare diseases.","H.R. 482/ S.350, the Newborn Screening Saves Lives\nReauthorization Act\nMACPAC Accelerated Approval Pathway Recommendations","Senate Finance Committee Drug Pricing Principles","H.R. 482/ S. 350, the Newborn Screening Saves Lives\nReauthorization Act\nBuild Back Better Act \nCures 2.0","Medicare Negotiation"]}